Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
Shiba-Ishii A, Johnson TW, Dagogo-Jack I, Mino-Kenudson M, Johnson TR, Wei P, Weinrich SL, McTigue MA, Walcott MA, Nguyen-Phuong L, Dionne K, Acker A, Kiedrowski LA, Do A, Peterson JL, Barth JL, Yeap BY, Gainor JF, Lin JJ, Yoda S, Hata AN. Shiba-Ishii A, et al. Nat Cancer. 2022 Jun;3(6):710-722. doi: 10.1038/s43018-022-00399-6. Epub 2022 Jun 20. Nat Cancer. 2022. PMID: 35726063 Free PMC article.
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.
Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, Dagogo-Jack I, Gadgeel S, Schultz K, Singh M, Chin E, Parks M, Lee D, DiCecca RH, Lockerman E, Huynh T, Logan J, Ritterhouse LL, Le LP, Muniappan A, Digumarthy S, Channick C, Keyes C, Getz G, Dias-Santagata D, Heist RS, Lennerz J, Sequist LV, Benes CH, Iafrate AJ, Mino-Kenudson M, Engelman JA, Shaw AT. Gainor JF, et al. Cancer Discov. 2016 Oct;6(10):1118-1133. doi: 10.1158/2159-8290.CD-16-0596. Epub 2016 Jul 18. Cancer Discov. 2016. PMID: 27432227 Free PMC article.
Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.
Dagogo-Jack I, Fabrizio D, Lennerz J, Schrock AB, Young L, Mino-Kenudson M, Digumarthy SR, Heist RS, Ali SM, Miller VA, Shaw AT. Dagogo-Jack I, et al. J Thorac Oncol. 2017 Oct;12(10):e155-e157. doi: 10.1016/j.jtho.2017.04.023. Epub 2017 May 9. J Thorac Oncol. 2017. PMID: 28499860 Free PMC article. No abstract available.
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer.
Gainor JF, Tseng D, Yoda S, Dagogo-Jack I, Friboulet L, Lin JJ, Hubbeling HG, Dardaei L, Farago AF, Schultz KR, Ferris LA, Piotrowska Z, Hardwick J, Huang D, Mino-Kenudson M, Iafrate AJ, Hata AN, Yeap BY, Shaw AT. Gainor JF, et al. JCO Precis Oncol. 2017;2017:PO.17.00063. doi: 10.1200/PO.17.00063. Epub 2017 Aug 16. JCO Precis Oncol. 2017. PMID: 29333528 Free PMC article.
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
Lin JJ, Zhu VW, Yoda S, Yeap BY, Schrock AB, Dagogo-Jack I, Jessop NA, Jiang GY, Le LP, Gowen K, Stephens PJ, Ross JS, Ali SM, Miller VA, Johnson ML, Lovly CM, Hata AN, Gainor JF, Iafrate AJ, Shaw AT, Ou SI. Lin JJ, et al. J Clin Oncol. 2018 Apr 20;36(12):1199-1206. doi: 10.1200/JCO.2017.76.2294. Epub 2018 Jan 26. J Clin Oncol. 2018. PMID: 29373100 Free PMC article.
86 results